Robeauté key facts
as of Oct 2026- Developer of a sub-millimetric medical device designed to diagnose and treat neuropathologies.
- Robeauté is valued at approximately $107.5M as of Oct 2026 (last reported valuation).
- It has raised $32.5M; the latest was Later Stage VC ($28.0M) in Jan 2025.
- Notable investors include MedTech Innovator, La French Tech, Phoenix Court, Cherry Ventures, Kindred Ventures — 13 tracked in total.
- Status: Privately Held (backing).
Robeauté's last reported valuation, Jan 2025. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch Robeauté: the Monday email on marks, rounds and moves
Robeauté funding rounds
No funding rounds for Robeauté are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Robeauté
13+Membership and data by Private Market View
Robeauté valuation
Robeauté's last reported valuation was $108 million in Jan 2025. No priced round, secondary trade or fund mark has surfaced since.
Robeauté investors
13 investors are on record for Robeauté, including MedTech Innovator, La French Tech, Phoenix Court and Cherry Ventures.
About Robeauté
Developer of a sub-millimetric medical device designed to diagnose and treat neuropathologies. The company's device is a nanobot that is smaller than a human cell that can enter the brain, navigate through tissues and cells and reach the targeted area without causing trauma, while the nanoelectronics included in the device lets it send critical information back to neuroscientists, enabling neurologists to get a device that can reach the human brain to treat neurological diseases and brain tumors.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2017
- Employees
- 39
- Website
- robeaute.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.